He EU Administrator It is confident that the possibility of achieving a positive decision through negotiations with legislators Pharmaceutical examination Despite the demands of the department in Europe, the original plan will not be changed.
Las Pharmaceutical companies They have recently urged the Commission to strengthen security Intellectual property Introduce new offers to support innovations, especially before this Business tensions Demands of growing and most favorable conditions.
Companies like French Sanofi And the Swiss giant Norvardis Press in a letter to reduce Cost controlsCurrent policies make the EU market less attractive compared to the US, where more medications are allowed.
To change the current plan, the Commission must formally withdraw it and put forward a new version because the assembly process is now in the hands Parliament And the EU Council. However, the commission has no intention of doing so.
“On the common and theoretical basis, if the files were prevented by colleges in the long run, there are no signs of progress, we can consider their withdrawal,” the commission spokesman said Wednesday. “But this is not like that. We are actively working with college artists to achieve a positive resolution“He said more.
European pharmacists fear business war with the United States.
The pressure of this sector is partly due to the immediate drug trade war with the United States. Although they have not yet been charged DutyAdministration Trump He started an investigation, which is the initial step towards its application. EU officials have also recognized their concern for the possibility of these rates to become a reality soon.
To make tensions worse may try to combine reports that emerged earlier this week Drug prices From the country to other developed countries. Pharmaceutical companies are now afraid of it European prices They are less, and Americans may also be forced to reduce, so the call to raise costs in Europe to prevent such maneuvers.
In response to the uncertainty business environment, many large pharmaceutical companies have announced that they are important Investments in the United States To prevent the impact of any payment. Novartis recently promised to invest $ 23,000 million (more than 20,326 million) in US production, at the same time, at the same time RoachHe has done this with an investment of $ 50,000 million (about 45,000 million euros) in Switzerland.
The commission is confident
Since the reform plan was presented in May 2023, the debates have advanced in the European Parliament, but the movements have rarely occurred in the House. However, the commission maintains confidence. “I don’t know that the conversations are so bad. We are confident of adoption,” the spokesman said.
He also highlighted such efforts Complex medical legal proposal And a recent call between the President’s President Ursula van der Leen and the pharmaceutical leaders, opened Conversation about professional worries.
“The Commission has promised to meet its requirements The main industry“We want the European market to be very attractive to novelty and pharmaceutical production, not only in economic view, but for all of our citizens,” the commission spokesman said.
